American International Group Inc. Sells 13,340 Shares of Bruker Co. (NASDAQ:BRKR)

American International Group Inc. cut its stake in Bruker Co. (NASDAQ:BRKRFree Report) by 9.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 126,298 shares of the medical research company’s stock after selling 13,340 shares during the period. American International Group Inc. owned approximately 0.09% of Bruker worth $9,280,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Massachusetts Financial Services Co. MA boosted its position in Bruker by 3.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 8,080,071 shares of the medical research company’s stock worth $593,724,000 after acquiring an additional 239,336 shares during the last quarter. RTW Investments LP increased its stake in Bruker by 14.3% in the 3rd quarter. RTW Investments LP now owns 3,381,703 shares of the medical research company’s stock valued at $210,680,000 after buying an additional 422,100 shares during the last quarter. Invesco Ltd. lifted its position in Bruker by 3.0% during the 3rd quarter. Invesco Ltd. now owns 1,950,145 shares of the medical research company’s stock worth $121,494,000 after buying an additional 56,869 shares in the last quarter. TD Asset Management Inc boosted its stake in shares of Bruker by 51.1% during the 4th quarter. TD Asset Management Inc now owns 1,664,779 shares of the medical research company’s stock worth $122,328,000 after buying an additional 562,684 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in shares of Bruker by 2.3% in the 4th quarter. Brown Advisory Inc. now owns 1,590,151 shares of the medical research company’s stock valued at $116,844,000 after acquiring an additional 35,873 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

BRKR has been the topic of several analyst reports. Citigroup upped their target price on Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. The Goldman Sachs Group increased their price objective on Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a report on Wednesday, April 10th. JPMorgan Chase & Co. raised shares of Bruker from a “neutral” rating to an “overweight” rating and raised their target price for the company from $60.00 to $90.00 in a research note on Wednesday, February 14th. Bank of America dropped their price target on shares of Bruker from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Monday, May 20th. Finally, Stifel Nicolaus decreased their price objective on shares of Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a research report on Monday, May 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Bruker has an average rating of “Moderate Buy” and an average price target of $85.00.

Read Our Latest Research Report on BRKR

Bruker Stock Performance

Shares of BRKR stock opened at $64.70 on Friday. Bruker Co. has a 52 week low of $53.79 and a 52 week high of $94.86. The company has a market capitalization of $9.40 billion, a price-to-earnings ratio of 23.53, a PEG ratio of 2.43 and a beta of 1.25. The company has a 50-day simple moving average of $78.15 and a 200 day simple moving average of $77.44. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81.

Bruker (NASDAQ:BRKRGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. The company had revenue of $721.70 million during the quarter, compared to analysts’ expectations of $729.88 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.64 earnings per share. On average, sell-side analysts predict that Bruker Co. will post 2.67 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 17th. Stockholders of record on Monday, June 3rd will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date of this dividend is Monday, June 3rd. Bruker’s dividend payout ratio is currently 7.27%.

About Bruker

(Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Featured Articles

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKRFree Report).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.